MedTrace Logo

CRC Post-surgical Assessment and Recurrence Monitoring

NCT03334890 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-11-07

No results posted yet for this study

Summary

The surgical therapeutic effect of stage II-IV CRC patients will be assessed by the plasma mSEPT9 assay, and patients will be followed up by the same assay for recurrence monitoring.

Conditions

Interventions

DIAGNOSTIC_TEST

plasma mSEPT9 level

the plasma level of methylated SEPT9

Sponsors & Collaborators

  • Chinese PLA General Hospital

    collaborator OTHER

  • First Hospitals affiliated to the China PLA General Hospital

    collaborator OTHER_GOV

  • 309th Hospital of Chinese People's Liberation Army

    collaborator OTHER

  • Beijing 302 Hospital

    collaborator OTHER

  • BioChain (Beijing) Science and Technology, Inc.

    lead INDUSTRY

Principal Investigators

  • Lele Song, M.D.,Ph.D. · The Chinese PLA 309th Hospital

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03334890 on ClinicalTrials.gov